findmyKOL
Clinical trialNCT00723359CompletedPhase 1Interventional

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

SponsorBiotest Pharmaceuticals CorporationEnrollment32Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Emory University Winship Cancer Institute

    Atlanta, Georgia, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Mount Sinai Medical Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BT062
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2008
Primary completion
30 Apr 2012
Completion
30 Apr 2012
Last update posted
18 Jul 2013
Registered enrollment
32
Registry id
NCT00723359
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.